OncoMatch/Clinical Trials/NCT06671548
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Is NCT06671548 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Relugolix for heavy menstrual bleeding.
Treatment: Relugolix — The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\[s\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Demographics
Prior therapy
Cannot have received: gonadotropin-releasing hormone (GnRH) agonist or antagonist
Previous treatment with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists for uterine fibroids has failed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06671548 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gonadotropin-releasing hormone (GnRH) agonist or antagonist disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify